Radiopharmaceutical developer Navidea Biopharmaceuticals said that an Australian clinical study plans to switch the radiopharmaceutical it is using to Navidea's NAV4694 beta-amyloid imaging candidate.
Instead of using carbon-11-labeled Pittsburgh Compound B (PiB) for its research initiative in Alzheimer's disease and mild cognitive impairment, the Australian Imaging, Biomarkers, and Lifestyle Flagship Study of Aging (AIBL) will now utilize Navidea's F-18-labeled beta-amyloid imaging agent, Navidea said.
In other Navidea news, the company reported that Dr. Jess Emery Jones has resigned as a member of the firm's board of directors for personal reasons, effective July 9. Jones has served on the board since April 2011, and the company said it expects to undertake a process in the near future to evaluate the board's composition.
